Simvastatin and disease stabilization in normal tension glaucoma: a cohort study.
Leung Dexter Y L, Li Felix C H, Kwong Yolanda Y Y, Tham Clement C Y, Chi Stanley C C, Lam Dennis S C
AI Summary
This study found simvastatin use was associated with reduced visual field progression in normal tension glaucoma patients, suggesting a potential protective effect warranting further investigation.
Abstract
Purpose
To investigate whether simvastatin use is associated with visual field (VF) stabilization in patients with normal tension glaucoma (NTG).
Design
Prospective cohort study (ClinicalTrials.gov Identifier: NCT00321386).
Participants
A total of 256 eyes from 256 Chinese subjects with NTG.
Methods
Patients were followed up at 4-month intervals for 36 months for VF progression per Anderson's criteria. Clinical parameters were checked for association with progression in multivariate analysis.
Main outcome measures
The primary outcome was the association between simvastatin use and VF progression.
Results
Thirty-one patients (12.1%) were taking simvastatin (statin+), and 225 patients (87.9%) were not taking simvastatin (statin-). Baseline age, gender, untreated intraocular pressure, VF indices, vertical cup-to-disc ratio, and central corneal thickness (CCT) were comparable between the 2 groups. There were significantly more patients with a history of hypercholesterolemia, systemic hypertension, and ischemic heart disease in the statin+ group. A total of 121 patients (47.3%) showed evidence of VF progression (mean rate of mean deviation loss was -0.30 decibel per year) during the 36 months of follow-up. Simvastatin use was among 8 of 121 patients (6.6%) who progressed compared with 23 of 135 patients (17.0%) who did not progress (P = 0.011). Logistic regression revealed that history of disc hemorrhage (relative risk [RR] 3.26; 95% confidence interval [CI], 1.21-8.76; P = 0.019), history of cerebrovascular accidents (RR 2.28; 95% CI, 1.03-5.06; P = 0.043), and baseline age (per 10 years older; RR 1.38; 95% CI, 1.08-1.76; P = 0.009) were significant risk factors for VF progression, whereas simvastatin use conferred a protective effect (RR 0.36; 95% CI, 0.14-0.91; P = 0.030).
Conclusions
Simvastatin use may be associated with VF stabilization in patients with NTG. A larger scale randomized controlled trial and cost-effectiveness analyses seem warranted.
MeSH Terms
Shields Classification
Related Articles5
Risk Factors for Visual Field Deterioration in the United Kingdom Glaucoma Treatment Study.
Randomized Controlled TrialEffects of Brimonidine and Timolol on the Progression of Visual Field Defects in Open-angle Glaucoma: A Single-center Randomized Trial.
Randomized Controlled TrialThe effect of Ca2(+) -antagonist on visual field in low-tension glaucoma.
Clinical TrialThe effect of pilocarpine on the glaucomatous visual field.
Clinical TrialComputerized perimetric monitoring and study of scotomatous fluctuations in timolol-treated open-angle glaucoma patients.
Observational StudyIs this article assigned to the wrong chapter(s)? Let us know.